Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jazz submits complete responses for Luvox

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Jazz Pharmaceuticals announces FDA's acceptance of a complete response to an "approvable" letter for Luvox CR (fluvoxamine maleate extended-release capsules), setting a user fee date at December 22. The NDA seeks claims for treatment of obsessive compulsive disorder and social anxiety disorder. FDA also has accepted the submission of Solvay Pharmaceuticals' complete response to its approvable letter for Luvox immediate-release tablets, setting the action date at December 21. Jazz licensed U.S. marketing rights to Luvox CR and Luvox from Solvay in January. Jazz expects to launch Luvox CR in the U.S. during the first quarter of 2008. The firm had its initial public offering in May (1Pharmaceutical Approvals Monthly June 2007, p. 6)...

You may also be interested in...

Targanta’s Noninferiority Study Design Could Be Regulatory Hurdle For Oritavancin

Targanta may need to conduct additional clinical trials of its intravenous antibiotic oritavancin if FDA does not accept the company's use of a 15 percent noninferiority delta in its Phase III trial, according to the firm's initial public offering prospectus filed May 11 with the Securities & Exchange Commission.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts